针对癌症预防与控制的基于人群的研究，接触“难以触及”的性取向和性别多样化群体：在线调查数据收集与管理方法

Reaching the "Hard-to-Reach" Sexual and Gender Diverse Communities for Population-Based Research in Cancer Prevention and Control: Methods for Online Survey Data Collection and Management.

作者信息

Myers Katie J, Jaffe Talya, Kanda Deborah A, Pankratz V Shane, Tawfik Bernard, Wu Emily, McClain Molly E, Mishra Shiraz I, Kano Miria, Madhivanan Purnima, Adsul Prajakta

机构信息

Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, United States.

Department of Internal Medicine, School of Medicine, University of New Mexico, Albuquerque, NM, United States.

出版信息

Front Oncol. 2022 Jun 8;12:841951. doi: 10.3389/fonc.2022.841951. eCollection 2022.

DOI:10.3389/fonc.2022.841951

PMID:35756657

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9213655/

Abstract

PURPOSE

Around 5% of United States (U.S.) population identifies as Sexual and Gender Diverse (SGD), yet there is limited research around cancer prevention among these populations. We present multi-pronged, low-cost, and systematic recruitment strategies used to reach SGD communities in New Mexico (NM), a state that is both largely rural and racially/ethnically classified as a "majority-minority" state.

METHODS

Our recruitment focused on using: (1) Every Door Direct Mail (EDDM) program, by the United States Postal Services (USPS); (2) Google and Facebook advertisements; (3) Organizational outreach emails to publicly available SGD-friendly business contacts; (4) Personal outreach flyers at clinical and community settings across NM. Guided by previous research, we provide detailed descriptions on using strategies to check for fraudulent and suspicious online responses, that ensure data integrity.

RESULTS

A total of 27,369 flyers were distributed through the EDDM program and 436,177 impressions were made through the Google and Facebook ads. We received a total of 6,920 responses on the eligibility survey. For the 5,037 eligible respondents, we received 3,120 (61.9%) complete responses. Of these, 13% (406/3120) were fraudulent/suspicious based on research-informed criteria and were removed. Final analysis included 2,534 respondents, of which the majority (59.9%) reported hearing about the study from social media. Of the respondents, 49.5% were between 31-40 years, 39.5% were Black, Hispanic, or American Indian/Alaskan Native, and 45.9% had an annual household income below $50,000. Over half (55.3%) were assigned male, 40.4% were assigned female, and 4.3% were assigned intersex at birth. Transgender respondents made up 10.6% (n=267) of the respondents. In terms of sexual orientation, 54.1% (n=1371) reported being gay or lesbian, 30% (n=749) bisexual, and 15.8% (n=401) queer. A total of 756 (29.8%) respondents reported receiving a cancer diagnosis and among screen-eligible respondents, 66.2% reported ever having a Pap, 78.6% reported ever having a mammogram, and 84.1% reported ever having a colonoscopy. Over half of eligible respondents (58.7%) reported receiving Human Papillomavirus vaccinations.

CONCLUSION

Study findings showcase effective strategies to reach communities, maximize data quality, and prevent the misrepresentation of data critical to improve health in SGD communities.

摘要

目的

约5%的美国人口认定自己的性取向和性别与传统不同（SGD），然而针对这些人群的癌症预防研究有限。我们介绍了多管齐下、低成本且系统的招募策略，用于接触新墨西哥州（NM）的SGD群体，该州大部分地区为农村，在种族/族裔方面被归类为“少数族裔占多数”的州。

方法

我们的招募工作重点利用了：（1）美国邮政服务（USPS）的 Every Door Direct Mail（EDDM）计划；（2）谷歌和脸书广告；（3）向公开可用的对SGD友好的商业联系人发送组织外联电子邮件；（4）在新墨西哥州各地的临床和社区场所发放个人外联传单。在前人研究的指导下，我们详细描述了如何使用策略来检查欺诈性和可疑的在线回复，以确保数据完整性。

结果

通过EDDM计划共发放了27369份传单，通过谷歌和脸书广告获得了436177次展示。我们在资格调查中总共收到了6920份回复。对于5037名符合条件的受访者，我们收到了3120份（61.9%）完整回复。其中，根据基于研究的标准，13%（406/3120）为欺诈性/可疑回复并被剔除。最终分析包括2534名受访者，其中大多数（59.9%）报告是通过社交媒体听说这项研究的。在受访者中，49.5%年龄在31 - 40岁之间，39.5%为黑人、西班牙裔或美国印第安人/阿拉斯加原住民，45.9%的家庭年收入低于5万美元。超过一半（55.3%）出生时被指定为男性，40.4%被指定为女性，4.3%出生时被指定为双性人。跨性别受访者占受访者的10.6%（n = 267）。在性取向方面，54.1%（n = 1371）报告为同性恋，30%（n = 749）为双性恋，15.8%（n = 401）为酷儿。共有756名（29.8%）受访者报告曾被诊断患有癌症，在符合筛查条件的受访者中，66.2%报告曾做过巴氏涂片检查，78.6%报告曾做过乳房X光检查，84.1%报告曾做过结肠镜检查。超过一半的符合条件受访者（58.7%）报告接种过人乳头瘤病毒疫苗。